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Background: Mass spectroscopy analysis suggested low serum albumin and high immunoglobulin free light chain (sFLC) levels
may have diagnostic value in hepatocellular carcinoma (HCC). Our aims were to apply quantitative assays to confirm these
observations, determine their diagnostic utility, and investigate the mechanisms involved.
Methods: Albumin, sFLC, routine liver and renal function tests were measured in patients with chronic liver disease with (n¼ 102)
and without (n¼ 113) HCC. The discriminant performance was compared with the current standard serological test alpha-
fetoprotein (AFP) using receiver operating characteristic (ROC) and area under the curve (AUC) analyses.
Results: sFLC and serum albumin were each confirmed to have discriminatory utility in HCC with AUC values of 0.7 and 0.8,
respectively. sFLC were strongly correlated with gammaglobulin levels and both these were inversely related to serum albumin
levels. The discriminatory utility of sFLC was retained after adjusting for renal and liver function.
Conclusions: Serum levels of sFLC and albumin were strongly associated with HCC as predicted by mass spectroscopy.
Discrimination of HCC by AFP was improved by the addition of either albumin or sFLC. Larger prospective studies are required to
determine how AFP, sFLC and albumin might be combined in a useful diagnostic approach for HCC.
Early diagnosis of hepatocellular carcinoma (HCC) is widely
considered to be the key to effective therapy. Radical, potentially
curative treatments, such as surgical resection, radiofrequency
ablation and orthotopic liver transplantation are only applicable to
that minority of patients who present with, or who are detected by
screening to have, smaller tumours, typically o5 cm in diameter
(Bruix and Sherman, 2005). This observation has led to routine
screening/surveillance of patients at high risk of HCC, namely
those with advanced chronic liver disease and certain carriers of
the hepatitis B or C viruses (HBV, HCV). Both in the screening
situation and the clinical situation where it is required to determine
if HCC has developed in a patient with symptoms, an imaging
procedure, usually ultrasound, followed by a CT or MRI are the
primary diagnostic modalities supplemented where necessary with
histological confirmation by biopsy (Bruix and Sherman, 2005).
Characteristic imaging features such as arterial enhancement and
portal phase ‘washout’ have been recognised to be highly sensitive
and specific features for the diagnosis of HCC (Torzilli et al, 1999;
Sangiovanni et al, 2010). Nonetheless, such an approach is
expensive and ultrasound examination is time-consuming and
highly operator-dependent so, a simple serological diagnostic test
would be invaluable. Estimation of serum alpha-fetoprotein (AFP)
has been widely used in this respect and indeed it is well recognised
to be highly specific and useful in the clinical setting when levels
are elevated above a particular threshold typically set between 200
and 500 ngml 1 (Johnson, 2001). However, the role of AFP in the
screening setting remains controversial, some supporting its utility
(Marrero and El-Serag, 2011) and others, because of its low
*Correspondence: Professor PJ Johnson; E-mail: Philip.Johnson@liverpool.ac.uk
3Current address: University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust.
Received 2 October 2013; revised 15 January 2014; accepted 11 February 2014; published online 6 March 2014
& 2014 Cancer Research UK. All rights reserved 0007 – 0920/14
FULL PAPER
Keywords: hepatocellular carcinoma; free light chains; albumin; biomarker; serum; proteomic; alpha-fetoprotein
British Journal of Cancer (2014) 110, 2277–2282 | doi: 10.1038/bjc.2014.121
www.bjcancer.com |DOI:10.1038/bjc.2014.121 2277
sensitivity in the early stages of the disease, have suggested that
AFP has no role in the screening setting (Bruix and Sherman, 2005;
Bruix and Sherman, 2011).
In a search for an alternative or additional serum markers for
HCC, we and others (Poon et al, 2003; Schwegler et al, 2005; Ward
et al, 2006b) have used surface-enhanced laser desorption/
ionisation (SELDI) mass spectroscopy to profile the serum
proteomes of patients with HCC and chronic liver disease and
those with chronic liver disease alone with a view to identify a
specific HCC signature. Although our studies showed that, in
principle, there was a characteristic ‘signature’, the early studies did
not identify the proteins responsible for the discrimination and as
such were regarded as ‘black box’ models (Poon et al, 2003).
Subsequently, in a study of hepatitis C-related HCC, we developed
a model that appeared to have high sensitivity and specificity and
that performed well on an independent test set (Ward et al, 2006a).
Furthermore, we identified the most discriminatory of the
identified peaks as representing serum immunoglobulin free light
chains (sFLC) and albumin. Recognising that the spectroscopic
profiling techniques for measuring these proteins were only semi-
quantitative, and that is difficult to envisage a plausible explanation
for the apparent diagnostic value of sFLC or albumin, the model
was not pursued further.
More recently, a sensitive assay for sFLC has become available
(Bradwell et al, 2001) and it has been shown that concentrations of
sFLC are elevated in chronic liver disease (Assi et al, 2010). We
have, therefore, revisited this area to examine the extent to which
the mass spectroscopy-based prediction of diagnostic utility could
be confirmed when specific assays were used.
MATERIALS AND METHODS
Hundred and two subjects with HCC were recruited from patients
referred to the Queen Elizabeth Hospital, Birmingham, UK. For all
the patients, the diagnosis was established by histology or the
combination of characteristic radiology together with an elevated
AFP level according to international guidelines (Bruix and
Sherman, 2005). Control samples were recruited from 113 patients
who were attending out-patient clinics for chronic liver disease in
the same institution. The various aetiologies were classified as
HBV-related, HCV-related, alcoholic-related and other. The latter
group comprised patients with haemochromatosis, primary biliary
cirrhosis, non-alcoholic steatohepatitis, or cryptogenic cirrhosis.
The diagnosis of chronic liver disease was made on the basis of
liver biopsy and/or typical clinical and imaging features. None of
the control groups had evidence of HCC at the time when the
sample was taken or with a follow-up period of 9 months.
Samples were collected with full informed consent and after
approval by the local ethics committee, prospectively and
specifically for the purpose of biomarker discovery and validation.
Routine liver and renal function tests (including cystatin C) were
measured and the severity of the liver disease was defined
according to the Child’s classification (Child and Turcotte, 1964;
Pugh et al, 1973) and the model for end-stage liver disease (MELD)
score (Kamath and Kim, 2007). Standard liver and renal function
tests were measured using the Roche Modular Analytics system
(Roche Diagnostics Ltd, Burgess Hill, UK). Hepatitis B surface
antigen and anti HCV were measured using the Roche Hepatitis
system.
Samples were assessed for total IgG, total IgA and total IgM
(Dade Behring, Siemens, Germany), serum free kappa (FLCk) and
serum free lambda (FLCl) light chains (Freelite, The Binding Site
Group Ltd, Birmingham, UK) and cystatin C (The Binding Site
Group Ltd). The reference range used for the sFLC analysis were:
FLCk 3.3–19.4mg l 1, FLCl 5.71–26.3mg l 1 and FLC ratio
0.26–1.65 (Katzmann et al, 2002). The reference range for cystatin
C was 0.56–0.99mg l 1 and the reference range for IgG, IgA and
IgM were 6–16 g l 1, 0.8–4 g l 1 and 0.5–2 g l 1, respectively
(Ward et al, 2004).
Statistical analysis. Statistical analysis was conducted using
Stata11 (StataCorp, College Station, TX, USA). The distribution
of FLCk and FLCl was plotted in box and whisker format. One
extreme value of FLCk (592mg l 1) with a highly abnormal FLC
ratio of 619 suggesting undiagnosed multiple myeloma/B-cell
dyscrasia was excluded. In descriptive statistics, Mann–Whitney U
test was used to assess the difference in distribution of sFLC and
albumin between the HCC and the control group. Logarithmic
transformation was applied to transform skewed data to correct for
overdispersion. Univariate analysis was performed for each
potential biomarker and serum parameter. Receiver operating
characteristic (ROC) analysis was used to assess the discriminant
performance of various biomarkers alone and in combination by
comparing the area under the curve (AUC). Serum AFP was used
as the current standard serological test for comparison and as a
baseline to determine whether sFLC or albumin could add
discriminatory power. A P-value of o0.05 was considered
statistically significant.
RESULTS
There was a highly significant increase in the concentration of both
FLCk and FLCl in the HCC patients (median of 34.81mg l 1
and 32.50mg l 1 for the HCC patients vs 18.20mg l 1 and
18.20mg l 1 for the control group, respectively, Po0.0001,
Mann–Whitney U test) (Figure 1A and B). Serum albumin levels
were signficantly lower in the HCC patients (medians of 37 g l 1 in
the HCC group and 45 g l 1 in the control group, Po0.0001,
Mann–Whitney U test) (Figure 1C). Levels of sFLC varied with
disease aetiology. In particular, the elevation of both FLCk
and FLCl was most marked in HCV-positive HCC patients
(Figure 1A and B).
Both albumin and either of the light chains had discriminatory
power with AUC ROC values between 0.73 and 0.77, respectively
(Figure 2). We then used multivariant logistic regression analysis to
assess the impact of sFLC when adjusted for individuals’ renal
function (as measured by creatinine or cystatin C) and/or liver
function (as measured by bilirubin, INR, or MELD). Both cystatin
C and MELD were significant in univariate analyses but both
dropped out of the model at 95% significance when either of the
sFLC were included into the model. Being aware that the standard
serological marker for HCC was serum AFP, we then examined the
extent to which either of the light chains or serum albumin
increases the diagnostic accuracy of AFP. The AUCs of FLCk and
FLCl were 0.91 and 0.90, respectively, when each was individually
combined with AFP (Figure 3). However, their impact was no
longer significant when serum albumin was included into the
model. The simple combination of albumin (AUC¼ 0.77) and AFP
(AUC¼ 0.87) was marginally more effective, than sFLC, with an
AUC of 0.92 (Figure 3).
As noted in Figure 1, most values within the control group fell
within the reference range, but in the HCC group, levels were
signifcantly higher across all aetiology groups. Gamma globulin
was moderately directly related to both FLCs (kand l) with an
R2 figure of 0.37 and 0.33, respectively, while it was moderately
inversely related to serum albumin with an R2 value of 0.34
(Figure 4A–C).
Finally, we explored the relationship between serum albumin
and gamma globulin as assessed by the difference between total
protein and albumin, or by individual immunoglobulin subgroups,
that is, IgG, IgA and IgM. There was a moderate inverse
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relationship between serum albumin and the difference between
total protein and albumin (i.e., the gamma globulin fraction) with
an R2 value of 0.42 (Figure 5A). Among all the immunoglobulins,
the relationship of IgG and albumin was most akin to the overall
gamma globulin in relation to albumin as indicated by equal slopes
(Figure 5B).
DISCUSSION
The data presented here validate the conclusions of our original
SELDI study using quantitative assays in a large independent
patient cohort (Ward et al, 2006a). We confirm that the most
significant changes identified by SELDI (albumin and sFLC) (Ward
et al, 2006a) indeed do have a considerable discriminatory
potential.
AFP is the standard serological test for HCC and returned an
AUC value of 0.87. By simply combining either albumin or sFLC
with AFP, an impressive AUC ROC value of 40.90 was obtained.
However, sFLC concentrations correlated closely with albumin,
and combining sFLC and albumin with AFP did not further
improve the AUC. Serum AFP and albumin are simple, cheap and
are routinely used in hospital laboratories for the assessment of
liver disease (Carr et al, 2007; Leerapun et al, 2007; Sterling et al,
2007). Therefore, these observations indicate that albumin used in
combination with AFP, might be a useful diagnostic screening test
for HCC, although this would require further validation in larger
prospective studies.
A low serum albumin level has been consistently associated with
a markedly increased risk of HCC. Thus, Wong et al, (Wong et al,
2010) using a large prospective cohort of patients with HBV-
related chronic liver disease, showed that low serum albumin, at
the time of entry into the study, was a key determinant of
subsequent HCC development. Nagao and Sata (Nagao and Sata,
2010) reported that, in a population-based study, in an area of high
HCV endemicity, hypoalbuminaemia was associated with signifi-
cantly increased mortality, particularly from HCC. Bonis et al
(1999) similarly found albumin to be a predictive factor for
HCC development among a large group of patients with chronic
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Figure 1. Serum levels of (A) free kappa, (B) free lambda light chains
and (C) albumin in relation to disease aetiology. Mann–Whitney U test
was used to assess the differences in distribution between HCC
(Cancer, n¼ 102) and the control group (n¼113) within the same
aetiology group. (*Po0.05, **Po0.005 and ***Po0.0005). Dashed
lines indicate the upper and the lower reference values.
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Figure 2. ROC curves for serum free kappa, serum free lambda and
albumin.
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Figure 3. ROC curve for serum albumin and AFP and their
combinations.
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hepatitis C infection. Above an albumin level of 41 g l 1, the risk of
HCC was only 3% compared with 40% for an albumin level below
41 g l 1. These authors considered a standard hepatological
interpretation of hypoalbuminaemia, that is, a reflection of poor
synthetic liver function (Schuppan and Afdhal, 2008). Others,
however, have questioned this and suggested that the hypoalbu-
minaemia may be related to the level of hypergammaglobulinaemia
as depression of albumin is consistent across a wide range of
diseases and inversely proportional to the gamma globulin levels
(Keshgegian, 1984). This was the case in the present study, both in
the HCC patients, the control subjects and in the group as a whole.
The reason for an elevation of gamma globulin in chronic liver
disease is again unclear, but seems likely to reflect an increased
exposure of gastrointestinal antigens to the systemic circulation as
a result of portal hypertension.
Elevated sFLCs occur in several chronic conditions particularly
those with generalised B-cell activation including systemic lupus
erythematosus (Aggarwal et al, 2011), rheumatoid arthritis and
Sjo¨rgrens syndrome (Gottenberg et al, 2007), and have been shown
to correlate significantly with disease activity (Aggarwal et al,
2011). Elevated sFLC have also been shown to be associated with
an increased risk of non-Hodgkin’s lymphoma in patients with
HCV (Terrier et al, 2009) or HIV (Landgren et al, 2010), and are
associated with poorer overall survival in chronic lymphocytic
leukaemia patients (Maurer et al, 2011). The association between
disease activity and sFLC was stronger than for immunoglobulin
levels, suggesting that sFLC may act as more sensitive surrogate
markers of B cell function (Landgren et al, 2010; Aggarwal et al,
2011).
In the current study, sFLC concentrations were significantly
elevated in the HCC patients, who were HBV or HCV-positive.
Antibodies to HBV and HCV viral epitopes are more frequently
detected in patients with HCC than in patients with cirrhotic liver
disease and are often evident before the development of HCC and
prior to elevations in AFP (Hann et al, 2004). Elevated sFLC may
reflect the developing B-cell response to viral infection and could
provide an early marker of HCC onset in virally infected patients.
In addition, as sFLCs have been implicated in the induction of
chronic inflammatory disease, and have been shown to bind to
carcinoma cells (van der Heijden et al, 2006) and other
intracellular and extracellular proteins (van der Heijden et al,
2006), sFLC could potentially influence the onset of HCC. Further
work is required to elucidate the role of sFLC in HCC.
Overall, there are two possible interpretations of our data.
Firstly, low serum albumin, as a result of poor ‘synthetic liver
A
B
C
0
50
100
150
Fr
ee
 k
ap
pa
 (m
g l
–
1 )
0 10 20 30 40
Gamma globulin (g l–1)
0
50
100
150
Fr
ee
 la
m
bd
a 
(m
g l
–
1 )
0 10 20 30 40
Gamma globulin (g l–1)
20
30
40
50
60
Al
bu
m
in
 (g
 l–1
)
0 10 20 30 40
Gamma globulin (g l–1)
Figure 4. Correlation between gammaglobumin and (A) serum free
kappa, (B) serum free lambda and (C) albumin.
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function’ is compensated for by a rise in gamma globulin as a
homoeostatic response to maintain plasma oncotic pressure
and that the elevation of sFLC is simply a consequence of
this hypergammaglobulinaemia. Alternatively, as suggested by
Keshgegian (1984), the primary event may be the hypergam-
maglobulinaemia. In any event, this interpretation would suggest
that any of these three parameters (low albumin, and raised
gamma globulins or sFLC) somehow reflect an aspect of liver
function that is permissive to HCC development.
The observation that a combination of albumin and AFP both
appear to have some diagnostic utility individually, but more so in
combination, one rising and one falling in the presence of HCC,
may still be noteworthy as the two proteins have a high degree of
sequence homology (Law and Dugaiczyk, 1981; Belanger et al,
1994). AFP is often described as ‘fetal albumin’. Thus, levels of
albumin are low in the fetus but rise rapidly, immediately after
birth, whereas our current results appear to suggest the reverse
happens during malignant change. It is conceivable that the rise in
AFP and fall in albumin represents a recapitulation of the fetal
state or a block in differentiation during malignant change, at the
fetal stage.
In conclusion, we have identified two easily quantifiable serum
markers that can be combined individually with AFP to improve
the discrimination of HCC patients from patients with chronic
liver disease. However, an important question to address is, to what
extent albumin and sFLC changes may address the limited
sensitivity of AFP for early HCC detection. This would require
suitable diagnostic thresholds to be established for each marker.
Additional prospective studies are required to determine how a
combination of albumin, sFLC and AFP may be used to predict
risk of HCC onset or to identify cirrhotic patients at a higher risk
of developing HCC, who would benefit from more frequent
surveillance.
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